专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2018188730A1 RNA FOR TREATMENT OF AUTOIMMUNE DISEASES 审中-公开
公开(公告)号：WO2018188730A1
公开(公告)日：2018-10-18
申请号：PCT/EP2017/058651
申请日：2017-04-11
申请人： BIONTECH RNA PHARMACEUTICALS GMBH , TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH , UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
发明人： SAHIN, Ugur , KREITER, Sebastian , KRIENKE, Christina , PETSCHENKA, Jutta , KRANZ, Lena, Mareen , DIKEN, Mustafa
IPC分类号： A61K39/00 , A61K48/00
摘要： The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.

12. 发明申请

WO2014180490A1 PREDICTING IMMUNOGENICITY OF T CELL EPITOPES 审中-公开
标题翻译：预测T细胞抗体的免疫原性
公开(公告)号：WO2014180490A1
公开(公告)日：2014-11-13
申请号：PCT/EP2013/001400
申请日：2013-05-10
申请人： BIONTECH AG , TRON - Translationale Onkologie an der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH , UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
发明人： SAHIN, Ugur , TADMOR, Arbel David , CASTLE, John Christopher , BOEGEL, Sebastian , LÖWER, Martin
IPC分类号： A61K39/00 , G06F19/18
CPC分类号： G06F19/18 , A61K39/0011 , C12Q1/6886 , C12Q2600/156
摘要： The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.
摘要翻译：本发明涉及预测T细胞表位的方法。特别地，本发明涉及用于预测肽或多肽如肿瘤相关新抗原的修饰是否是免疫原性的方法。本发明的方法特别适用于提供特异于患者肿瘤的疫苗，因此在个体化的癌症疫苗的背景下。

13. 发明申请

WO2014071963A1 METHOD FOR CELLULAR RNA EXPRESSION 审中-公开
标题翻译：细胞RNA表达方法
公开(公告)号：WO2014071963A1
公开(公告)日：2014-05-15
申请号：PCT/EP2012/004673
申请日：2012-11-09
申请人： BIONTECH AG , TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH , UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
发明人： SAHIN, Ugur , BEISSERT, Tim , POLEGANOV, Marco , HERZ, Stephanie
IPC分类号： C12N15/67 , C12N15/68 , C12N15/69
CPC分类号： C12N5/0696 , C12N2501/24 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/605 , C12N2501/606 , C12N2501/608 , C12N2501/727 , C12N2510/00
摘要： The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells.
摘要翻译：本发明涉及在细胞中表达RNA，特别涉及提高RNA表达细胞的活力。具体地，本发明提供了在细胞中表达RNA的方法，其包括以下步骤：通过细胞外IFN与IFN受体的接合并抑制细胞中的细胞内IFN信号传导。因此，通过细胞外IFN阻止IFN受体的接合并抑制细胞中的细胞内IFN信号传导允许RNA重复转移到细胞中。

14. 发明申请

WO2013143555A1 RNA FORMULATION FOR IMMUNOTHERAPY 审中-公开
标题翻译： RNA免疫组化制剂
公开(公告)号：WO2013143555A1
公开(公告)日：2013-10-03
申请号：PCT/EP2012/001319
申请日：2012-03-26
申请人： BIONTECH AG , TRON - Translationale Onkologie an der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH , UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ , SAHIN, Ugur , HAAS, Heinrich , KREITER, Sebastian , DIKEN, Mustafa , FRITZ, Daniel , MENG, Martin , KRANZ, Lena, Mareen
发明人： SAHIN, Ugur , HAAS, Heinrich , KREITER, Sebastian , DIKEN, Mustafa , FRITZ, Daniel , MENG, Martin , KRANZ, Lena, Mareen
IPC分类号： A61K9/127 , A61K39/00 , A61K48/00
CPC分类号： A61K48/0033 , A61K9/1272 , A61K39/0011 , A61K48/0025 , A61K2039/53 , A61K2039/55555
摘要： The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.
摘要翻译：本发明涉及免疫治疗领域，特别是肿瘤免疫治疗领域。本发明提供用于在全身给药后将脾脏中的抗原提呈细胞例如树突状细胞（DC）递送RNA的药物制剂。特别地，本文描述的制剂能够在全身给予抗原编码RNA之后诱导免疫应答。

15. 发明申请

WO2018167151A1 ANTIGEN RECEPTORS AND USES THEREOF 审中-公开
公开(公告)号：WO2018167151A1
公开(公告)日：2018-09-20
申请号：PCT/EP2018/056399
申请日：2018-03-14
申请人： BIONTECH CELL & GENE THERAPIES GMBH , TRON – TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH , UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
发明人： VOSS, Ralf Holger , SAHIN, Ugur , SIMON, Petra , BIRTEL, Matthias , CASPAR, Janina
IPC分类号： C07K14/705 , C07K14/725 , A61K38/17
摘要： The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.

16. 发明申请

WO2016062659A1 METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER 审中-公开
标题翻译：用于诊断和治疗癌症的方法和组合物
公开(公告)号：WO2016062659A1
公开(公告)日：2016-04-28
申请号：PCT/EP2015/074136
申请日：2015-10-19
申请人： BIONTECH AG , TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH , UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
发明人： SAHIN, Ugur , PARET, Claudia , BENDER, Christian , VORMBROCK, Kirsten , BAREA ROLDAN, Diana , HUBICH, Stefanie , HARTMANN, Christoph
IPC分类号： A61K47/48 , C07K16/30 , C12Q1/00 , G01N33/574 , A61K35/00
CPC分类号： G01N33/57484 , A61K35/17 , A61K38/03 , A61K48/005 , C07K14/4747 , C07K16/30 , C12Q1/6886 , G01N33/5011 , G01N33/57407 , G01N2800/52
摘要： The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues,in particular tumors of the central nervous system (CNS) such as glioma, in particular glioblastoma and which represent targets for therapy or diagnosis of tumor diseases in a subject.
摘要翻译：本发明涉及鉴定肿瘤组织，特别是中枢神经系统（CNS）如神经胶质瘤（特别是胶质母细胞瘤）的特征的核酸和氨基酸序列，其代表治疗或诊断肿瘤疾病的靶点在一个主题

17. 发明申请

WO2014180569A1 PREDICTING IMMUNOGENICITY OF T CELL EPITOPES 审中-公开
标题翻译：预测T细胞抗体的免疫原性
公开(公告)号：WO2014180569A1
公开(公告)日：2014-11-13
申请号：PCT/EP2014/001232
申请日：2014-05-07
申请人： BIONTECH AG , TRON - Translationale Onkologie an der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH , UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
发明人： SAHIN, Ugur , TADMOR, Arbel David , CASTLE, John Christopher , BOEGEL, Sebastian , LÖWER, Martin
IPC分类号： A61K39/00 , G06F19/18
CPC分类号： G06F19/18 , A61K39/0011 , C12Q1/6886 , C12Q2600/156
摘要： The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and. thus, in the context of personalized cancer vaccines.
摘要翻译：本发明涉及预测T细胞表位的方法。特别地，本发明涉及用于预测肽或多肽如肿瘤相关新抗原的修饰是否是免疫原性的方法。本发明的方法特别适用于提供特异于患者肿瘤的疫苗。因此，在个性化的癌症疫苗的背景下。

18. 发明申请

WO2011073091A1 3-(INDOLYL)-OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE DERIVATIVES FOR USE IN THE TREATMENT OF COLON AND GASTRIC ADENOCARZINOMA 审中-公开
标题翻译： 3-（吲哚基）-OR 3-（AZAINDOLYL） - 用于治疗结肠和胃肠腺癌的4-芳基酰亚胺衍生物
公开(公告)号：WO2011073091A1
公开(公告)日：2011-06-23
申请号：PCT/EP2010/069349
申请日：2010-12-10
申请人： Johannes Gutenberg-Universität Mainz , Universitätsmedizin der Johannes Gutenberg-Universität Mainz , DANNHARDT, Gerd , PLUTIZKI, Stanislav , KRAMB, Jan-Peter , MÜLLER, Annett , MÖHLER, Markus
发明人： DANNHARDT, Gerd , PLUTIZKI, Stanislav , KRAMB, Jan-Peter , MÜLLER, Annett , MÖHLER, Markus
IPC分类号： A61K31/404 , A61K31/437 , A61P35/00
CPC分类号： A61K31/404 , A61K31/437 , A61K2300/00
摘要： The present invention relates to the use of a compound of formula (I) wherein R 1 and R 3 are as defined in the description and R 2 is a phenyl group which is substituted with 2 or 3 C 1 -C 6 alkoxy groups, or a physiologically acceptable salt thereof, or a solvate of the compound of formula (I) or of the salt thereof, for treatment of colorectal or gastric adenocarcinoma.
摘要翻译：本发明涉及式（I）化合物的用途，其中R 1和R 3如说明书中所定义，R 2为被2或3个C 1 -C 6烷氧基取代的苯基或其生理上可接受的盐，或式（I）化合物或其盐的溶剂化物，用于治疗结肠直肠癌或胃腺癌。

19. 发明申请

WO2023046960A1 METHOD FOR RECONSTRUCTING A BRAIN NETWORK 审中-公开
公开(公告)号：WO2023046960A1
公开(公告)日：2023-03-30
申请号：PCT/EP2022/076704
申请日：2022-09-26
申请人： UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
发明人： GONZALEZ-ESCAMILLA, Gabriel , GROPPA, Sergiu
IPC分类号： G16H30/40 , G16H50/20 , A61B5/055
摘要： According to the disclosure, a method for reconstructing a brain network (205), comprises providing, in a memory of a computing device, an image of at least a section of a subject's brain (201); determining, in a processing unit of the computing device, a three-dimensional volume model (202) of the section of the subject's brain (201); segmenting, by the processing unit, the volume model (202) into a plurality of sub-volumes, each sub-volume corresponding to an anatomical subfield of the subject's brain (201) and having a volume value; for each of the sub-volumes, determining, by the processing unit, a modified volume for the sub-volume, wherein determining said modified volume comprises calculating said modified volume based on the volume value of the sub-volume and variables multiplied with constants, wherein the constants are constants determined for a population, comprising a plurality of individuals, to which the subject belongs; for each combination of two sub-volumes, determining, by the processing unit, a similarity between the sub-volumes, based on a comparison of the respective modified volume for each of the sub-volumes; and determining, by the processing unit, a brain network (205) for the section of the subject's brain (201). The brain network (205) comprises nodes (206), each node (206) representing one of the sub-volumes, and edges (207), each edge (207) connecting two nodes (206) and being indicative of the determined similarity between the sub-volumes. At least one of the steps from the group of storing the brain network (205) in the memory of the computing device, displaying the brain network (205) on a display unit of the computing device, and sending the brain network (205) to a remote computing device via a transmission unit of the computing device is performed. Further, a method for monitoring a brain network, a computing device, a computer program product and a computer-readable storage medium are provided.

20. 发明申请

WO2022106648A1 INHIBITORS OF THE TISSUE FACTOR-PROTEASE ACTIVATED RECEPTOR 2 (TF-PAR2) SIGNALING PATHWAY FOR USE IN THE TREATMENT OR PREVENTION OF HEART FAILURE (HF) AND ASSOCIATED OR RESULTING DISEASES 审中-公开
公开(公告)号：WO2022106648A1
公开(公告)日：2022-05-27
申请号：PCT/EP2021/082355
申请日：2021-11-19
申请人： UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
发明人： RUF, Wolfram , WENZEL, Philip
IPC分类号： A61K38/17 , A61K45/06 , C07K16/00 , G01N33/50
摘要： The present invention relates to novel inhibitors of the Tissue Factor-Protease Activated Receptor 2 (TF-PAR2) signaling pathway for use in the treatment or prevention of heart failure (HF). The invention furthermore relates to an in-vitro method for identifying a subject at risk for developing ischemic heart failure (IHF) or adverse remodeling following myocardial infarction (Ml), comprising the steps of i. determining the tissue factor (TF) cytoplasmic domain phosphorylation in myeloid cells and the levels of active TGF-β1 in a biological sample collected from said subject, ii. comparing the level of phosphorylation of the TF cytoplasmic domain and the level of active TGF-β1 in said biological sample with the level of phosphorylation of the TF cytoplasmic domain and the level of active TGF-β1 in a normal, healthy subject, wherein increased levels of phosphorylation of the TF cytoplasmic domain and active TGF-β1 are indicative for an increased risk of developing IHF or adverse remodeling following Ml.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式